Overview

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Status:
Completed

Trial end date:
2020-07-01

Target enrollment:

Participant gender:

Summary

This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to evaluate efficacy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Academic Myeloma Consortium
Criterium, Inc.

Collaborators:

Amgen
Celgene Corporation
Criterium, Inc.
Onyx Pharmaceuticals

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Pomalidomide
Thalidomide